Cobra Biologics, part of the Cognate BioServices family, and CombiGene AB, a gene therapy company in the Nordic region, have signed agreements covering Good Manufacturing Practice (GMP) production of two essential plasmids needed for the manufacture of CG01, a gene therapy designed for the treatment of drug resistant focal epilepsy.   The agreement follows the recent announcement that Cobra had successfully completed production of the GMP master cell banks to produce three plasmids used as start...